Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study tested a new drug, TQ05105, in 13 people who had severe graft-versus-host disease (aGVHD) after a stem cell transplant and did not respond to steroids. The goal was to see if the drug is safe and can help control the disease. The study was stopped early, so results are…

This study tested a new combination of cancer drugs (bemarituzumab plus anlotinib) against a standard treatment (tislelizumab) for people with extensive-stage small cell lung cancer. The goal was to see if the new combo could delay cancer growth or improve survival. However, the …

This study tested a new drug called TQB3616 combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study was stopped …

This early-stage study tested a new drug called TQB3720 in 192 men with advanced prostate cancer that had stopped responding to hormone therapy. The main goal was to find a safe dose and see how the drug moves through the body. The study was stopped early, so results are limited.

This study tested a new drug combination for people with advanced endometrial cancer or uterine sarcoma who had not yet received treatment. The combination included an immunotherapy drug (TQB2450) plus chemotherapy, with or without a targeted therapy (anlotinib). The goal was to …

This study tested two experimental drugs, TQ05105 and TQB3909, taken together as tablets for people with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the combination could shrink an enlarged spleen and improve symptoms. The trial enrol…

This study tested a new drug combination (TQB3912, fulvestrant, and TQB3616) in people with advanced HR-positive, HER2-negative breast cancer. The goal was to find the best dose and see if the treatment shrank tumors or slowed cancer growth. The trial was stopped early after enro…

This early-stage study tested a new drug combination (TQB2223 plus penpulimab) in 22 adults with advanced liver cancer. The goal was to see if the treatment was safe and could shrink tumors. However, the trial was terminated early, so results are limited.

This study tested a new drug called TQB3616 for people with a rare type of fat tissue cancer called dedifferentiated liposarcoma that could not be removed by surgery. The goal was to see if the drug could slow down cancer growth compared to a placebo. The trial was stopped early …